Pfizer and LianBio link up to bring new drugs to China

19 November 2020

US pharma giant Pfizer (NYSE: PFE) and Sino-American biotech LianBio have entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China.

LianBio’s aim is to catalyze the development and accelerate availability of ‘paradigm-shifting’ medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. It was founded by the privately-owned hedge fund sponsor Perceptive Advisors.

Konstantin Poukalov, managing director, Perceptive Advisors, and executive chairman, LianBio, said: “We are honored to partner with Pfizer, a significant pioneer in the industry, to build upon their extensive commercial engine in Greater China, as well as tap into their relationships with leading physicians specializing in a broad range of therapeutic areas.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK